Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | EHMT2 | Q96KQ7 | 12/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25489623 | 0.88 | ACHE (0.57) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL20745564 | 0.85 | ACHE (0.69) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL31458727 | 0.85 | ACHE (0.69) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL20745971 | 0.82 | ACHE (0.74) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL20756932 | 0.81 | ACHE (0.72) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL20745999 | 0.80 | ACHE (0.56) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL20745998 | 0.78 | ACHE (0.57) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL20756358 | 0.78 | EHMT2 (0.57) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL25489634 | 0.77 | ACHE (0.58) | ACHEEHMT2APPBCHETP53 | |
| SCHEMBL20746217 | 0.77 | EHMT2 (0.59) | ACHEEHMT2APPBCHETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668863-B1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | ACHE 1893/4885EHMT2 2/4885APP 3949/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | ACHE 1893/4885EHMT2 2/4885APP 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.